A H₂O₂-activatable nanoprobe for diagnosing interstitial cystitis and liver ischemia-reperfusion injury via multispectral optoacoustic tomography and NIR-II fluorescent imaging

Junjie Chen¹,³, Longqi Chen¹,³, Yinglong Wu², Yichang Fang¹, Fang Zeng¹✉, Shuizhu Wu¹✉ & Yanli Zhao²✉

Developing high-quality NIR-II fluorophores (emission in 1000–1700 nm) for in vivo imaging is of great significance. Benzothiadiazole-core fluorophores are an important class of NIR-II dyes, yet ongoing limitations such as aggregation-caused quenching in aqueous milieu and non-activatable response are still major obstacles for their biological applications. Here, we devise an activatable nanoprobe to address these limitations. A molecular probe named BTPE-NO₂ is synthesized by linking a benzothiadiazole core with two tetraphenylene groups serving as hydrophobic molecular rotors, followed by incorporating two nitrophenyloxoacetamide units at both ends of the core as recognition moieties and fluorescence quenchers. An FDA-approved amphiphilic polymer Pluronic F127 is then employed to encapsulate the molecular BTPE-NO₂ to render the nanoprobe BTPE-NO₂@F127. The pathological levels of H₂O₂ in the disease sites cleave the nitrophenyloxoacetamide groups and activate the probe, thereby generating strong fluorescent emission (950–1200 nm) and ultrasound signal for multi-mode imaging of inflammatory diseases. The nanoprobe can therefore function as a robust tool for detecting and imaging the disease sites with NIR-II fluorescent and multispectral optoacoustic tomography (MSOT) imaging. Moreover, the three-dimensional MSOT images can be obtained for visualizing and locating the disease foci.
Fluorescence imaging technique holds a great promise as an intuitional and effectual way to track and understand various biological and physiological processes because of its advantages such as high sensitivity and real-time manner. Fluorescent imaging in the second biological window (emission in 1000–1700 nm, NIR-II) has attracted increasing interests due to its immanent advantages including low light scattering and weak autofluorescence in tissues, which enables real-time imaging at much deeper depth with higher resolution in organism and could be employed for more accurate diagnosis of disease, monitoring of therapy course and understanding disease development13–15. Therefore, developing high-quality NIR-II fluorophores for in vivo imaging is of great significance and has a major impact on the field of preclinical and clinical applications.

Among the NIR-II organic fluorescent dyes, those based on benzothiadiazole backbone have aroused extensive attention because of the ease of extending their fluorescent emission into the NIR-II range, excellent photostability and large stoke shifts5–8. For NIR-II fluorescent dyes based on benzothiadiazole, the common molecular structure is the donor–acceptor–donor (D–A–D) structure with the electron-accepting benzothiadiazole as the core and hydrophobic aryls as the electron-donating groups at the both sides of the core9–12. The integration of the two electronic donors (D) and an electronic acceptor (A, benzothiadiazole) is conducive to realizing a large and planar conjugation architecture, and thus effectively extending the fluorophore’s emission to the NIR-II range13–16. Prime limitations associated with such large and planar conjugation include poor water solubility and the accompanying fluorescence quenching because of the aggregation in aqueous medium, and these limitations have become the major obstacles for exploiting these types of fluorophores in biological applications.

To overcome the aggregation-caused quenching (ACQ) in aqueous milieu for benzothiadiazole-core NIR-II fluorophores, the aggregation-induced emission (AIE) feature has been employed in the design of the molecular structure17–22. Unlike common fluorophores for which aggregation quenches their fluorescent emission, AIE-active fluorophores exhibit even stronger fluorescent emission as the aggregation extent is enhanced. In the AIE-active fluorophores, the molecular rotors dissipate the excited energy via non-radiative pathway by means of intramolecular movements such as rotations when the fluorophores are in the molecularly-dissolved form, whereas if the fluorophores are in the aggregation form, the movements of the rotors are frozen and the excited energy dissipates via radiative pathway and subsequently produces strong fluorescent emission23–27. Some hydrophobic molecular rotors such as triphenylamine and tetraphenyldihylenyl (TPE) and their derivatives have often been employed as the donor groups at the both sides of benzothiadiazole core to make NIR-II fluorophores for bioimaging28–30. By this way, such disadvantage as poor water-solubility could be turned into an advantageous asset for devising NIR-II fluorophores on the strength of AIE. However, for benzothiadiazole-core NIR-II fluorophores, another major limitation still needs to be circumvented, namely, these fluorophores are generally inert probes which cannot respond to specific stimuli to achieve biomarker-activated detection or imaging. Inert probes give out unvaried or “always-on” signals that constitute the added background noise, while activatable probes produce signals only if they encounter or react with the target biomarker, hence the detection or imaging using activatable probes would have much higher sensitivity with negligible background noise and could effectively avoid giving false positive signals31–36. If only AIE-active NIR-II fluorophores based on benzothiadiazole core can be converted into biomarker-activatable probes, the probes would perceptibly hold a great potential for more extensive applications including clinical translation.

Optoacoustic (photoacoustic) imaging is an emerging modality that collects ultrasound waves generated by photoexciting contrast agents in tissues and produces images with high resolution and penetration depth37–44. A dual-mode probe applicable in both NIR-II fluorescence and optoacoustic imaging is highly advantageous because it provides mutually corroborated information. Reactive oxygen species (ROS) play essential roles in the progression of various inflammatory diseases such as drug-induced liver injury, liver ischemia/reperfusion injury and interstitial cystitis. At the foci of these diseases, the elevated level of H2O2 and other ROS lead to the intensified oxidative stress and subsequently cause tissue injuries and exacerbate inflammation. Hence endogenous hydrogen peroxide can serve as a promising signal in situ biomarker for these diseases. As ROS has a very short half-life (e.g., a few seconds and less), the in situ and non-invasive detection of the disease marker would be ideal for accurately locating the disease sites with the aid of robust probes via NIR-II fluorescence imaging and optoacoustic imaging.

In light of the above and endeavoring to devise an activatable two-mode NIR-II probe for disease diagnosis in a sensitive and non-invasive way, we developed a de novo nanoprobe namely BTPE-NO2@F127 (Fig. 1). To obtain the nanoprobe, a benzothiadiazole-based core (compound 6, as shown in Supplementary Fig. 1) is first synthesized by connecting benzothiadiazole with two TPE, which is then linked with two nitrophenyloxacetamide groups at its both ends to afford the molecular probe BTPE-NO2. The molecular probe (BTPE-NO2) is then encapsulated with the FDA-approved amphiphilic and biocompatible polymer Pluronic F127 (poly(ethylene oxide)-block-poly(propylene oxide)-block-poly(ethylene oxide)), affording the nanoprobe BTPE-NO2@F127.

In this work, the design strategy for the probe BTPE-NO2 lies in the following three aspects: (1) The two TPE groups serve as the hydrophobic molecular rotors, so as to make the chromophore BTPE-NH2 AIE-active and simultaneously enhance the aggregation extent due to the increased hydrophobicity and conjugation; (2) The two nitrophenyloxacetamide groups on both ends of the benzothiadiazole core serve not only as the recognition moiety for the biomarker H2O2, but also as an emission quencher owing to their electron-withdrawing ability; (3) Encapsulation of molecular probe BTPE-NO2 by Pluronic F127 ensures necessary biocompatibility and water-dispersibility for biological applications. Importantly, owing to existence of the strong electron-withdrawing nitro group (NO2) on the recognition moiety, the electronic state of the molecular probe can be significantly altered after the recognition moiety being cleaved. Without the presence of H2O2, this nanoprobe is almost non-fluorescent due to the existence of the two fluorescence quenchers and the absorption is centering around 615 nm, whereas the H2O2 at pathological level in the disease sites (e.g., in liver or bladder) cleaves the nitrophenyloxacetamide and produces the activated chromophore (BTPE-NH2), thereby red-shifting the absorption band to 680–850 nm and generating strong NIR-II fluorescent emission in the range of 950–1200 nm.

Results
Preparation and characterization of the nanoprobe BTPE-NO2@F127. The nanoprobe BTPE-NO2@F127 was employed in the diagnosis of three inflammatory diseases in mouse models, including the trazodone-induced liver injury, the liver ischemia/reperfusion injury, and the interstitial cystitis, so as to evaluate its capability for detecting and imaging inflammatory disease sites via responding to the in situ endogenous biomarker. Our results perceptively indicate that the nanoprobe BTPE-NO2@F127 can function as a tool for biomarker-activated detection and imaging of...
diseases through the NIR-II fluorescent imaging and the multi-spectral optoacoustic tomography (MSOT) imaging. In addition, the three-dimensional (3D) MSOT images can be attained by employing this nanoprobe, providing 3D information for accurately pinpointing the disease foci.

The molecular probe BTPE-NO$_2$ and the activated probe BTPE-NH$_2$ were synthesized in accordance with the procedures outlined in Supplementary Fig. 1, and resultant products and intermediates were characterized by $^1$H NMR, $^{13}$C NMR and mass spectrometry (Supplementary Figs. 2–18). The BTPE-NO$_2$ was then encapsulated with Pluronic F127 to afford the nanoprobe BTPE-NO$_2$@F127. To verify the AIE feature of BTPE-NH$_2$, its fluorescence intensities in the mixture of dimethyl sulfoxide (DMSO)/water (good solvent: DMSO, poor solvent: water) with varying water fraction were measured. Changing the water fraction can finely tune the solvent mixture’s dissolving ability and correspondingly the extent of BTPE-NH$_2$ aggregation. As shown in Fig. 2a, b, as the water fraction increases, the emission intensity of BTPE-NH$_2$ solution increases obviously, exhibiting a typical AIE feature. As the water fraction reaches 99%, the fluorescence intensity for BTPE-NH$_2$ shows about 12.8-fold enhancement as compared to that in DMSO solution.

Owing to the strong hydrophobicity and high conjugation of the probe BTPE-NO$_2$, the high encapsulation efficiency (98%) can be achieved upon being encapsulated by Pluronic F127, and the loading capacity of BTPE-NO$_2$ in the nanoprobe BTPE-NO$_2$@F127 is determined as 9.3%. Transmission electron microscopy (TEM) reveals that the nanoprobe BTPE-NO$_2$@F127 has relatively uniform spherical morphology with a diameter of about 37 nm (inset of Fig. 2c), and the particle size distribution of the nanoprobe BTPE-NO$_2$@F127 measured by the dynamic light scattering (DLS) is shown in Fig. 2c. There are no obvious changes in particle size for the nanoprobe BTPE-NO$_2$@F127 in PBS (pH 7.4) or in PBS containing 10% FBS upon being stored for 7 days (Supplementary Fig. 19a), indicating that the nanoprobe BTPE-NO$_2$@F127 exhibits good storage stability. Additionally, an obvious Tyndall phenomenon can be observed for the nanoparticle dispersion before and after incubation with H$_2$O$_2$ under laser beam irradiation (inset of Supplementary Fig. 19b).

Optical and acoustic response of BTPE-NO$_2$@F127 toward H$_2$O$_2$. The concentration-dependent fluorescence and absorption
spectra for BTPE-NO2@F127 after treatment with H2O2 of different concentrations were measured in PBS (10 mM, pH = 7.4) under 37 °C (Fig. 2d–g). The fluorescence intensity at 1028 nm increases with increasing H2O2 levels (Fig. 2d–g), while the nanoprobe BTPE-NO2@F127 is weakly emissive in the absence of H2O2. The absorption spectra for the nanoprobe BTPE-NO2@F127 before or after H2O2 incubation are presented in Fig. 2f. Before responding to H2O2, the nanoprobe BTPE-NO2@F127 exhibits the maximum absorption at about 615 nm. After responding to H2O2, the maximum absorption red-shifts to about 680 nm and the absorption band ranges from 600–850 nm. It is obvious from Fig. 2f, g that, with increasing H2O2 concentration, the absorption spectra exhibit a red-shift and the absorbance at 680–850 nm increases evidently. As shown in
Supplementary Fig. 20a, b, the fluorescence spectra of the nanoprobe BTPE-NO2@F127 after incubation with H2O2 show an emission peak at 938 nm and a shoulder peak at 1028 nm, while the absorption peak exhibits a 65 nm red-shift from 615 nm to 680 nm. Additionally, the fluorescence spectra of BTPE-NH2@F127 and BTPE-NO2@F127 were also measured using 615 nm (the maximum absorption of BTPE-NO2@F127) or 808 nm as the excitation light (Supplementary Fig. 20c, d). These data clearly indicate that the increased fluorescence intensity is the result of the probe’s response to H2O2. The stability of BTPE-NO2@F127 after responding to H2O2 was investigated as well. It can be clearly seen from Supplementary Fig. 20e that the size and zeta potential of nanoparticles display almost no change for 72 h after responding to H2O2. Furthermore, the fluorescent intensity at 1028 nm remains almost unchanged for 72 h after responding to H2O2 (Supplementary Fig. 20f). The data signify that the BTPE-NO2@F127 probe after responding to H2O2 has a good stability. The time-dependent fluorescence and absorption spectra of BTPE-NO2@F127 nanoprobe after treatment with 100 μM H2O2 for various time periods are displayed in Supplementary Fig. 21, showing that the reaction between the nanoprobe BTPE-NO2@F127 and H2O2 is complete in about 60 min. The results indicate that BTPE-NO2@F127 nanoprobe is suitable for NIR-II fluorescence imaging.

The optoacoustic intensities in the range of 680–900 nm for the BTPE-NO2@F127 nanoprobe upon the incubation with different concentrations of H2O2 are presented in Fig. 2h and Supplementary Fig. 22a. The linear relationship between the optoacoustic intensities and H2O2 levels (0–100 μM) is clearly observable (Fig. 2h). In addition, the nanoprobe BTPE-NO2@F127 upon incubation with H2O2 and its activable form BTPE-NH2 show much better photostability compared to indocyanine green (ICG) that is FDA-approved for clinical application under the continuous irradiation with 808 nm laser for 60 min (Fig. 2i). To study the anti-interference properties and selectivity of the BTPE-NO2@F127 nanoprobe toward H2O2, a variety of potential interfering substances, such as the biomolecules and ions that are biologically relevant, were tested. It can be seen that the nanoprobe BTPE-NO2@F127 displays good selectivity and anti-interference properties toward H2O2 (Supplementary Fig. 23). The detection limit of BTPE-NO2@F127 toward H2O2 was determined as 0.74 μM (3σ/slope, Supplementary Fig. 22b). Moreover, the maximum absorption of BTPE-NH2 slightly blue-shifts in the low-polar solvents such as toluene and dichloromethane (Supplementary Fig. 22c). BTPE-NH2 is non-emissive (fluorescence quenching) in high-polar solvents such as dimethylformamide and dimethyl sulfoxide, while becoming emissive in the low-polar solvents (toluene or dichloromethane, Supplementary Fig. 22d). The molar extinction coefficient of BTPE-NH2 is 0.58 × 10^4 L·mol⁻¹·cm⁻¹ at 615 nm and that of BTPE-NH2 is 1.07 × 10^4 L·mol⁻¹·cm⁻¹ at 680 nm in pH 7.4 PBS containing 5% DMSO. The mass extinction coefficient of BTPE-NO2@F127 is 4.45 mL·mg⁻¹·cm⁻¹ at 615 nm and BTPE-NH2@F127 is 10.32 mL·mg⁻¹·cm⁻¹ at 680 nm in pH 7.4 PBS.

It is posited that upon reaction with H2O2, the probe compound BTPE-NO2 is converted into the chromophore BTPE-NH2 (the activated form of the probe). To verify this response mechanism, 1H NMR spectra were measured for the probe BTPE-NO2 before and after its reaction with H2O2. The probe BTPE-NO2 before reaction with H2O2 shows the proton peaks at 8.99 ppm, 8.58–8.59 ppm and 8.33–8.34 ppm (Supplementary Fig. 24), corresponding to the protons of amide group and the protons on the ortho-position and the meta-position of nitrophenyl respectively. After complete reaction of the probe BTPE-NO2 with H2O2, the above-mentioned proton peaks disappear as a result of the product BTPE-NH2 being formed. Moreover, mass spectrum was measured for the probe BTPE-NO2 after its incomplete reaction with H2O2. The peak at m/ z = 1577.4082 [M + H]⁺ and the peak at m/z = 1223.3958 [M + H]⁺ correspond to the probe BTPE-NO2 and the chromophore BTPE-NH2, respectively ( Supplementary Fig. 25a). In addition, the absorption and emission spectra for BTPE-NH2@F127 and BTPE-NO2@F127 upon reaction with H2O2 were measured (Supplementary Fig. 25b, c). It is clearly apparent that their spectra are quite similar. These results signify that upon reaction with H2O2, the probe BTPE-NO2 is transformed into the chromophore BTPE-NH2 (the activated form of the probe). In addition, density functional theory (DFT) calculations were performed for the electronic structures of BTPE-NO2 and BTPE-NH2. As shown in Supplementary Fig. 26, the highest occupied molecular orbitals (HOMO) of both BTPE-NO2 and BTPE-NH2 are delocalized along the conjugated backbone, and the lowest unoccupied molecular orbital (LUMO) of the BTPE-NO2 is located mainly on the nitrophenyloxycetamide units, while the LUMO of BTPE-NH2 is located mainly on the central benzothiadiazole core. The energy gap between the HOMO and LUMO in BTPE-NH2 is 1.85 eV, which is lower than that for BTPE-NO2 (2.01 eV). The DFT calculations also confirm the spectral difference between BTPE-NO2 and BTPE-NH2.

Cell experiments and biosafety of BTPE-NH2@F127. The ability of the nanoprobe BTPE-NH2@F127 to respond to H2O2 in living cells was evaluated by cell imaging studies. First, the cytotoxicity of the nanoprobe BTPE-NH2@F127 was evaluated using RAW264.7 cells by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. As shown in Supplementary Fig. 27, the nanoprobe BTPE-NH2@F127 exhibits low cytotoxicity toward the cell line. Notably, even after being incubated with the nanoprobe BTPE-NH2@F127 at concentration of 500 μg mL⁻¹ (equivalent to 46.5 μg mL⁻¹ BTPE-NO2), the viabilities of the cells are still higher than 85%. Hence, the low toxic nanoprobe BTPE-NH2@F127 is suitable for cell imaging. Afterwards, the cell imaging was performed upon RAW264.7 cells being incubated with different concentrations of H2O2 (Supplementary Fig. 28). The NIR-II fluorescence intensities and optoacoustic intensities enhance upon the exposure of RAW264.7 cells to higher H2O2 concentrations (from 0 to 200 μM). The above results suggest that the nanoprobe BTPE-NH2@F127 is promising for detecting the biomarker H2O2 with optoacoustic imaging and NIR-II fluorescence imaging.

The biosafety of the nanoprobe BTPE-NH2@F127 was investigated by histological analysis for the major organs and the body weight change monitoring of the healthy mice intravenously (i.v.) injected with the nanoprobe BTPE-NH2@F127 and saline (as the control) respectively. As shown in Supplementary Figs. 29 and 30a, it is evident that there are no apparent histopathological morphology aberrancies in the organ tissues from the control and the group injected with BTPE-NH2@F127, and there are insignificant differences in the body weights for the control group and the group injected with BTPE-NH2@F127. The observations denote that BTPE-NH2@F127 nanoprobe exhibits high biosafety. Moreover, the aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels show no abnormality in the group of healthy mice with post nanoprobe injection for 7 days compared to the control (healthy mice injected with saline, Supplementary Fig. 30b). To evaluate the biodistribution, pharmacokinetics, and long-term clearance of the nanoparticles, BTPE-NH2@F127 was employed in the healthy mice. The nanoparticles are first observable in bloodstream and then cleared from the bloodstream with accumulation in the liver within 4 h (Supplementary Fig. 30c). Furthermore, the nanoparticles are distributed mainly in the liver.
and eventually cleared out of the body via the intestine. Most of BTPE-NH₂@F127 are cleared out post injection for 48 h (Supplementary Fig. 30d).

Imaging of interstitial cystitis mouse model by BTPE-NO₂@F127. Based on the above encouraging results confirming that the nanoprobe BTPE-NO₂@F127 can effectively respond to H₂O₂ and thus generate NIR-II fluorescent and optoacoustic signals, we then applied the nanoprobe for diagnosing several inflammatory diseases. Interstitial cystitis is an inflammatory condition of bladder featured with pelvic pain as well as urine frequency and urgency. It is hard to diagnose, as currently no specific clinical testing exists to diagnose the disease and hence it is often diagnosed upon other conditions being ruled out⁴⁵. There exists the enhanced production of ROS including H₂O₂ in the bladder in the case of interstitial cystitis, hence H₂O₂ can serve as an in situ biomarker for the disease⁴⁶,⁴⁷. We thus employed the nanoprobe BTPE-NO₂@F127 to diagnose interstitial cystitis via responding to the in situ biomarker H₂O₂. Cyclophosphamide (CYP, trade name Cytoxan or Neosar) is an FDA-approved chemotherapy medication, and inducing interstitial cystitis is one of its well-known adverse effects⁴₈,⁴⁹. It is known that CYP causes interstitial cystitis through the following process: once CYP enters the body and is metabolized in the liver, an active antitumor drug and a toxic metabolite (acrolein) are produced, and acrolein is excreted in the urine through kidney, bladder and urethra, during this process acrolein induces bladder damage by injuring the bladder’s transitional epithelium⁵₀. Therefore, we used CYP to establish the interstitial cystitis mouse model by intraperitoneal injection of varied doses of CYP. As shown in Fig. 3a, when CYP was intraperitoneally administered to female mice for 24 h, the nanoprobe BTPE-NO₂@F127 (BTPE-NO₂: 2.3 mg kg⁻¹) was intravesically injected into the mice, and then the NIR-II fluorescent imaging and MSOT imaging were performed. From the NIR-II fluorescent imaging results (Fig. 3b and Supplementary Fig. 31a), the fluorescence intensities increase gradually with time and reach the maximum in about 90 min post injection of BTPE-NO₂@F127, and then gradually fade due to the metabolism. The overexpressed H₂O₂ in the bladder activates the nanoprobe and thus gives out the NIR-II fluorescent signals. At 90 min post BTPE-NO₂@F127 injection, the group of mice with high CYP dose (150 mg kg⁻¹) exhibits higher fluorescence intensity compared to the low CYP dose (75 mg kg⁻¹) group and the control group (healthy mice), suggesting that higher dose of CYP causes more severe injuries in bladder region.

Unlike fluorescent imaging that generates proton signals, the optoacoustic imaging produces ultrasound signals as the reporting signals upon excitation, and hence it avoids strong proton scattering by biological tissues and offers high penetration depth with high spatiotemporal resolution³⁷–⁴³. For MSOT imaging, the biological samples are irradiated by lasers with multiple wavelengths, and the ultrasound signals produced by various photoabsorbers (endogenous photoabsorbers including hemoglobin and exogenous probes) in the samples are detected and collected⁵¹–⁵⁵. Then, spectral un-mixing based on specific absorption (or optoacoustic) spectrum of each photoabsorber is
conducted to separately visualize signals from individual photoabsorber. In addition to its advantages including high spatial resolution and large penetration depth for imaging, MSOT imaging can generate 3D images after the cross-sectional (tomographic) images being stacked and rendered as the 3D maximum intensity projection images, enabling accurate location of the site of interest (e.g., the disease site) non-invasively and in a spatiotemporal way.

The MSOT imaging with the aid of the nanoprobe BTPE-NO2@F127 (BTPE-NO2: 2.3 mg kg\(^{-1}\); the nanoprobe was administered via intravesical injection) was performed for interstitial cystitis mouse model, and the results are shown in Fig. 4 and Supplementary Fig. 31. A female mouse cryosection image that corresponds to the bladder cross-section is shown in Supplementary Fig. 31b, and the mean MSOT intensities for the bladder region in the cross-sectional images are presented in Supplementary Fig. 31c. By comparing the cross-sectional MSOT image to a cryosection image (Fig. 4a and Supplementary Fig. 31b), it is apparent that the MSOT signals are indeed at bladder site, and the signals reach the maximum at about 90 min upon intravesical injection of the nanoprobe BTPE-NO2@F127. The 3D orthogonal-view MSOT images (3D MIP images) are obtained to locate the bladder inflammation, and the 3D MSOT images for the control (healthy mice treated with saline) and the model mice groups upon treatment with varied doses of CYP are exhibited in Supplementary Fig. 31d. With the 3D MSOT images, the location of the bladder in inflammation can be clearly observed. In addition, histological analyses (with H&E staining) were conducted for the bladder tissues from the control and the interstitial cystitis model mice (Fig. 4b). It is lucid that for the model groups treated with CYP, hemorrhage, edema and urothelial sloughing can be observed, and the group with higher CYP dose suffers more severe conditions. These results confirm that the nanoprobe BTPE-NO2@F127 can detect the inflamed bladder via responding to the in situ biomarker H\(_2\)O\(_2\) and thus diagnose the interstitial cystitis non-invasively via the NIR-II fluorescent and MSOT imaging, and the 3D MSOT image could identify and locate the disease site.

Imaging of liver injury mouse model by BTPE-NO2@F127.

Trazodone is a clinical medicine for treating depression, and high daily dose of trazodone would cause liver injury. It is well known that ROS is overexpressed in hepatic region in case of liver injury, and thus hepatic H\(_2\)O\(_2\) acts as the endogenous biomarker for liver damage or injury\(^{56,57}\). Trazodone (with its structure shown in Fig. 5a) was employed to stimulate hepatic injury in male mice by intraperitoneal injection of varied doses of trazodone for three consecutive days. 6 h after the last injection of trazodone (on the third day), the serum levels of the enzyme ALT from different groups were measured by Elisa kits. It was observed that the serum ALT levels of the mice increase with the increasing trazodone dosage (Fig. 5b), confirming the increasing severity of liver injury with increasing trazodone dose. Next, we employed the nanoprobe BTPE-NO2@F127 to image the liver injuries. The NIR-II fluorescence images for the control group and the groups administered with different amounts of trazodone for three consecutive days are shown in Fig. 5c and Supplementary Fig. 32. For the mice treated with trazodone, no fluorescence can be observed at 0 min before injection of the nanoprobe BTPE-NO2@F127, while the...
Fig. 5 Application of nanoprobe BTPE-NO2@F127 in trazodone-induced liver injury mouse model. a Molecular structure of trazodone. b Serum levels for the enzyme ALT of different groups (n = 5 animals per group). c Typical photographs under halogen light (serving as bright-field images) and NIR-II fluorescence images for the control group (mice administered with saline), and the mice pretreated with 50 mg kg$^{-1}$, 100 mg kg$^{-1}$ and 200 mg kg$^{-1}$ trazodone at 0 min or at 120 min after i.v. injection of the nanoprobe BTPE-NO2@F127. Blue circle: liver region. Color bar: L: $6.0 \times 10^2$, H: $6.0 \times 10^4$ (arb. units). d Mean NIR-II fluorescence intensities at ROI (circled with blue curve) for liver site of the mice in c. n = 5 animals per group. e Mean NIR-II fluorescence intensities of the major organs corresponding to NIR-II fluorescent images in f. n = 5 animals per group. f Representative ex vivo NIR-II fluorescent images for the dissected organs (heart, liver, spleen, lung, and kidney) from different groups at 120 min after i.v. injection of BTPE-NO2@F127. Color bar: L: $6.0 \times 10^2$, H: $6.0 \times 10^4$ (arb. units). g Typical 3D MSOT images for the mice at 120 min after BTPE-NO2@F127 injection. White dotted circle: liver region. Scale bar: 3 mm. h H&E stained liver sections of different groups (n = 5 animals per group. The experiments were repeated independently three times with similar results). Color bar: L: $6.1 \times 10^3$, H: $4.1 \times 10^3$ (arb. units). Scale bar: 20 μm. Data with error bars are all presented as mean ± SD. F.I. fluorescence intensity, ALT alanine aminotransferase.
fluorescent intensities increase with the increasing dose of trazodone at 120 min after the injection of the nanoprobe BTPE-NO2@F127. The quantified intensities of the region of interest (ROI) covering the liver region (Fig. 5c and Supplementary Fig. 32) are presented in Fig. 5d and Supplementary Fig. 33, which provide intuitive data for fluorescence images. The fluorescent intensities of the excised organs (kidney, heart, liver, lung and spleen) from different groups of mice at 120 min after the treatment of the nanoprobe BTPE-NO2@F127 are shown in Fig. 5e, and the NIR-II fluorescent images of these organs are revealed in Fig. 5f. The liver exhibits much stronger fluorescence than other major organs such as heart, spleen, lung and kidney, and the fluorescence intensities from the groups treated with different doses of trazodone show the dose-dependent behavior.

Afterwards, the nanoprobe BTPE-NO2@F127 was utilized to observe the liver injury stimulated by trazodone via MSOT imaging. Supplementary Fig. 34 presents cross-sectional images of healthy mice that were pretreated with saline (control) and the mice that were pretreated with different doses of trazodone before (0 min) and after i.v. injection of the BTPE-NO2@F127 nanoprobe for varied times. The upper panel of the figure displays the overlay of the image from activated nanoprobe and that from 850 nm single-wavelength excitation (namely, the grayscale background serving as an anatomical reference), and the lower panel provides the color images showing the biodistribution of the activated nanoprobe’s signals via spectral unmixing. The signals of activated nanoprobe are apparently observable and progressively enhance with time after the injection of the BTPE-NO2@F127 nanoprobe, and their intensities attain the peak level at 120 min. The mean signal intensity for the liver region (ROI) in different groups of mice is given in Supplementary Fig. 35. Moreover, the 3D orthogonal-view MSOT images covering the liver region of different groups of mice are presented in Fig. 5g, which are capable of reflecting 3D information on liver injury of different groups of mice. It can be seen that weak MSOT signals appear in the hepatic area of the mice without trazodone treatment after nanoprobe injection, because low ROS (including H2O2) level exists in the liver region in healthy mice. For the groups subject to treatment of varied amounts of trazodone (50, 100 or 200 mg kg−1), prominent MSOT signals are found at their liver regions, and the signals are stronger for the mice treated with higher trazodone dose, indicating the mice with higher dose of trazodone suffer more severe liver damage. These results signify that the increase in H2O2 level in the hepatic region resulted from liver injury can be detected using MSOT imaging in a spatiotemporal way. Afterwards, the mice pretreated with 0, 50, 100 and 200 mg kg−1 of trazodone were euthanized, from which the main organs were acquired and underwent ex vivo imaging. As revealed by Supplementary Figs. 36 and 37, the livers display strongest MSOT signals among these main organs. Next, histological analysis (H&E staining) for the tissue sections of livers from different groups of mice was conducted as well (Fig. 5h). The liver tissue section from the control group shows normal morphology with no obvious aberration, while those from the mice treated with trazodone display nuclear cytoplasmic separation, vacuolization and hydropic degeneration, and high dose of trazodone enhances the liver injury severity.

Furthermore, we used the nanoprobe to image another inflammatory disease. Liver ischemia-reperfusion (I/R) injury is a major complication in a variety of clinical scenarios, such as liver resection, liver transplantation, hemorrhagic shock, resuscitation and trauma surgery, and it remains the main cause of mortality or morbidity because of graft rejection upon liver transplantation. In the case of liver I/R injury, ROS (including H2O2) is overexpressed in the hepatic region, which leads to local inflammatory responses and cell apoptosis and further aggravates liver injury. Herein, we employed the nanoprobe BTPE-NO2@F127 to detect the degree of liver injuries on account of its response to hepatic H2O2. The mice were treated with ischemia for 0 min (the sham group serving as the control), 30 min or 60 min, followed by reperfusion for 24 h. Figure 6a shows the liver I/R process of the mice. In the case of ischemia, the liver appears pale colored due to the blocked blood supply, while sanguineous perfusion is clearly observable upon the vascular clamp being removed. For the sham group and the I/R model groups, the nanoprobe BTPE-NO2@F127 was i.v. injected into different groups of mice and then the mice underwent MSOT imaging and NIR-II fluorescence imaging. The NIR-II fluorescence images and the fluorescence intensities of the liver region of the mice are shown in Fig. 6b, c. The liver area of the mice in the sham group exhibits weak fluorescence at 90 min or 120 min upon the injection of the nanoprobe BTPE-NO2@F127, while the liver areas of the ischemia groups show evident fluorescence. The long ischemia group (ischemia for 60 min) exhibits higher fluorescence intensities compared to the short ischemia group (ischemia for 30 min), because higher amount of hepatic H2O2 is generated for longer ischemia time and correspondingly more severe liver damages ensue for the long ischemia group. For the groups with 30 or 60 min of ischemia in the I/R process (Fig. 6d and Supplementary Fig. 38), the liver presents much stronger fluorescence among the main organs, which is consistent with the in vivo imaging results.

Then, the nanoprobe BTPE-NO2@F127 was used to detect liver I/R injuries via MSOT imaging. The related data are presented in Fig. 7a and Supplementary Fig. 39. Figure 7a presents the cross-sectional MSOT images of the mice from different groups at varied time points after i.v. injection of BTPE-NO2@F127. The quantified data of the MSOT intensity in the ROI for the liver region are presented in Fig. 7b and Supplementary Fig. 40. Serving as the reference for organ locations, the cryosection image of a male mouse that corresponds to mouse liver region is shown in Fig. 7c. The control (sham group) does not display remarkable MSOT signal in the liver region at 120 min after i.v. injection of BTPE-NO2@F127 nanoprobe (Fig. 7a, b), while the mice from the ischemia groups show obvious MSOT signal at 120 min, indicating the formation of liver injuries. As for the long ischemia group (ischemia 60 min), the signal in the liver region becomes much more conspicuous compared to the control (ischemia 0 min) or the short ischemia group (ischemia 30 min). To verify the relationship between I/R process and liver injury, we then measured the enzyme activities of serum ALT and AST by using Elisa kits. The I/R process leads to remarkable enhancement in the activities of these serum enzymes (Fig. 7d), proving that direct correlation between liver dysfunction and I/R process does exist, and the results are similar to literature reports.

As one of the first volume visualization methods, maximal intensity projection images (MIP images) usually serve as a method for 3D data in orthogonal views. In this study, we acquired the 3D orthogonal-view images. Figure 7e reveals the 3D MSOT images for the different groups of mice with I/R process (namely sham group, short ischemia group and long ischemia group) at 120 min after i.v. injection of the nanoprobe BTPE-NO2@F127. As for the group undergoing I/R process with longer time of ischemia (60 min), the injured liver can be distinctly observed with strong MSOT signals, and the volume (size) of the injured liver is much larger compared to the group undergoing I/R process with short time of ischemia (30 min). Next, dissected organs from different groups of mice after euthanasia were subjected to MSOT imaging (Supplementary Figs. 41 and 42). For the groups undergoing I/R process with 30 or 60 min of ischemia, the livers display much more evident MSOT signals than other organs, and the result verify the in vivo imaging observations. Moreover, the liver sections of the mice in different groups were...
analyzed via histological analyses (Fig. 7f). The inflammatory cell infiltration and vacuolization degeneration are clearly observable in the long ischemia (60 min) group or the short ischemia group (30 min) compared to the sham group, and the conditions are more serious in long ischemia group than those in the short ischemia group, indicating the mice with I/R process suffering severe hepatic injury.

**Discussion**

Benzothiadiazole-core chromophores possess promising advantages such as excellent stability, large stoke shift and ease of extending emission into NIR-II range. However, impediments including poor water solubility and resultant ACQ as well as non-activatable response still need to be circumvented before they can give a full play to their potentials in biological applications. In this study, we have shown that these impediments can be overcome by the design strategy through integrating biomarker-responsive moieties and adopting the self-assembly with encapsulation of the molecular probe.

The comparison between the nanoprobe BTPE-NO$_2$@F127 with other reported NIR-II fluorescent probes and optoacoustic (photoacoustic) probes, as well as their applications in mouse...
disease models clearly demonstrates that our nanoprobe outperforms other NIR-II and photoacoustic imaging probes in many ways, particularly in terms of activatable response and signal-to-background ratio (Supplementary Tables 1–3).

In summary, an activatable benzothiadiazole-core nanoprobe BTPE-NO2@F127 with AIE feature has been developed for in vivo NIR-II fluorescent imaging and MSOT imaging. The presence of pathological levels of H2O2 in the disease sites activates the nanoprobe through cleaving the recognition groups and generating the chromophore BTPE-NH2, thereby producing strong NIR-II fluorescent emission and optoacoustic signals. The nanoprobe is able to detect and image the trazodone-induced liver injury, the I/R liver injury and the interstitial cystitis in mouse models via responding to the in situ H2O2 biomarker. The nanoprobe could therefore serve as a robust tool to detect and image the disease sites with MSOT imaging and NIR-II fluorescent imaging. Moreover, the obtained 3D MSOT images are advantageous for visualizing the disease site with 3D information. The study herein unleashes the promising potential of benzothiadiazole-core molecules for optoacoustic imaging and NIR-II fluorescent imaging of specific diseases, and the strategy could offer insights for designing other large π-conjugated NIR-II chromophores for various biological applications.

Fig. 7 Application of nanoprobe BTPE-NO2@F127 in liver ischemia-reperfusion injury mouse model via MSOT imaging. a Representative cross-sectional MSOT images for different groups at 0 min and 120 min after i.v. injection of the nanoprobe BTPE-NO2@F127 (I ischemia, R reperfusion). Organ labeling: "1" represents spinal cord. White dotted circle: liver region. Scale bar: 3.0 mm. Color bar: L: 6.1 × 10^1, H: 4.1 × 10^3 (arb. units). b Mean MSOT intensities corresponding to ROI (white dotted line) in a. n = 5 animals per group. c Cryosection image of a male mouse with its cross-section location matching those in a. 1: Spinal cord; 2: Spleen; 3: Thoracic aorta; 4: Vena cava; 5: Liver; 6: Portal vein; 7: Intestines; 8: Stomach. The cryosection image is from CryoMOUSE™ atlas provided with the MSOT equipment for anatomical reference. d Serum levels of two enzymes ALT and AST from various groups. n = 5 animals per group. e Typical 3D MSOT images for different groups at 120 min post-injection of BTPE-NO2@F127 nanoprobe. "1" represents spinal cord. White dotted circle: liver region. Color bar: L: 6.1 × 10^1, H: 4.1 × 10^3 (arb. units). f Representative H&E staining of liver sections from different mouse groups (n = 5 animals per group. The experiments were repeated independently three times with similar results. Scale bar: 20 μm). Data with error bars are all presented as mean ± SD. I ischemia, R reperfusion, MSOT multispectral optoacoustic tomography.
Methods

Reagents. 4-Aminophenylboronic acid pinacol ester, 4,7-dibromo-5,6-dinitrobenzo[c][1,2,5] thiadiazole, 1,2-bis(4-bromophenyl)ethane-1,2-dione, iron powder, bis(pinacolato)diboran, bromotriphenylenylmethane, N-isodocosinimide (NIS), 4-nitrophenoxyglyoxylic acid, oxalyl chloride, Pd(PPh3)4, Pd(PPh3)2Cl2, and tributyl(3-methylthiophen-2-yl)stannane were purchased from Aldrich Reagents. Cyclophosphamide, H2O2, and tritiated hydrochloride were purchased from Sigma-Aldrich. DMSO and PBS (10 mM) were purchased from KeyGen Bio-Tech. Elisa kits for alanine aminotransferase (ALT) and aspartate transaminase (AST) were purchased from Shanghai Enzyme-linked Biotechnology Co. Ltd.

Optical properties of BTPE-NH2 for evaluating AIE feature. The NIR-II fluorescence emission spectra were recorded on a Bruker MAXIS IMPACT mass spectrometer. MALDI-TOF was recorded on a MALDI SYNAPT G2-Si mass spectrometer. Near-infrared II (NIR-II) fluorescence spectra were recorded on NIREQUEST512 spectrometer (excitation: 808 nm laser, emission range: 900–1700 nm). The absorption spectra were collected on a PerkinElmer Lambda 950 spectrophotometer. 1H NMR and 13C NMR spectra were measured on a Bruker Avance 300 MHz NMR Spectrometer. High resolution mass spectrometer (HR-MS) was used with a MALDI TOF-MS ESI (m/z) [M + H]+ [C26H27BO2Na]+ calc. 418.9942, found 418.9946.

Preparation of the nanoprobe BTPE-NO2@F127. Briefly, the amphiphilic polymer Pluronic F127 (F127, 20 mg) and BTPE-NO2 (2 mg) were dissolved in chloroform (1 mL), followed by sonication for 5 min at room temperature to form a homogeneous solution. Then, the chloroform was removed by rotary evaporator vacuum. The residue was added with BTPE-NH2 (60 mg, 0.05 mmol), triethylamine (56 μL, 0.4 mmol) and dichloromethane (5 mL), and stirred at room temperature for 1 h. The crude product was purified with hexane/ethyl acetate (2/1, v/v) as eluent by silica gel column chromatography to obtain green-solvent solid (35 mg, yield: 4%).

Synthesis of BTPE-NH2. Under nitrogen atmosphere, 4-nitrophenoxyglyoxylic acid (78 mg, 0.40 mmol) and oxalyl chloride (106 μL, 1.20 mmol) were dissolved in dichloromethane (5 mL) and stirred at 0 °C for 3 min, and then DMSO (20 μL) was added and refluxed at 45 °C. After 1 h, the solvent and excess oxalyl chloride were removed by rotary evaporator vacuum. The residue was added with BTPE-NH2 (50 mg, 0.06 mmol), triethylamine (56 μL, 0.4 mmol) and dichloromethane (5 mL), and stirred at room temperature for 1 h. The crude product was purified with hexane/ethyl acetate (2/1, v/v) as eluent by silica gel column chromatography to obtain green-solvent solid (35 mg, yield: 4%).

Synthesis of compound 5. 2-Methylthiophene-2-carboxaldehyde (2 M, 12 mL) aqueous solution were dissolved in 1,4-dioxane (48 mL) under nitrogen atmosphere. After stirring for 24 h, the mixture was cooled down to room temperature and extracted with ethyl acetate. The crude product was purified with silica gel column chromatography with hexane/dichloromethane (1:1, v/v) as the eluent to obtain the orange-red solid (790 mg, yield: 98%).

Synthesis of compound 6. Compound 5 (400 mg, 0.60 mmol) was added under nitrogen atmosphere for 24 h. After that, it was cooled down to room temperature, extracted with ethyl acetate and neutralized with NaHCO3 solution. The crude product was purified with silica gel column chromatography using hexane/dichloromethane (1:1, v/v) as the eluent to obtain the solid (400 mg, 0.60 mmol, yield: 96%). 1H NMR (600 MHz, DMSO-d6): δ 7.29 (s, 2H), 5.78 (s, 4H), 1.97 (s, 6H). HR-MS ESI (m/z) [M + H]+ [C26H27NO2S]+ calc. 418.9942, found 418.9946.

Synthesis of compound 4. Compound 3 (500 mg, 1.19 mmol, NIS (645 mg, 2.87 mmol), chloroform (5 mL) and acetic acid (5 mL) were added in a single-necked flask and stirred at 40 °C in the darkness for 24 h. After the reaction, the solvent was evaporated under reduced pressure. The crude product was dissolved in DMSO, added into ice water, and then filtered to collect the orange-red solid (520 mg, yield: 96%). 1H NMR (600 MHz, DCM-d6): δ 7.52–7.65 (m, 5H), 7.20–7.31 (m, 4H), 7.10–7.20 (m, 4H), 6.90–6.98 (m, 2H), 1.27 (s, 12H). HR-MS ESI (m/z) [M + H]+ [C26H27NO2S]+ calc. 418.9942, found 418.9946.

Synthesis of compound 3. Compound 2 (1250 mg, 3.27 mmol) was dissolved in K2CO3 (2 M, 6 mL) aqueous solution and THF (24 mL), and Pd(PPh3)4 (160 mg, 0.14 mmol) was added under nitrogen atmosphere. After stirring for 24 h, the mixture was cooled down to room temperature and extracted with ethyl acetate. The crude product was purified with silica gel column chromatography with hexane/dichloromethane (2:1, v/v) as eluent to obtain the white solid (320 mg, yield: 8%). 1H NMR (600 MHz, DMSO-d6): δ 7.86–7.64 (d, J = 8.4, 4H), 7.18–7.12 (m, 22H), 6.99–6.97 (m, 12H). HR-MS ESI (m/z) [M + H]+ [C26H27NO2S]+ calc. 418.9942, found 418.9946.

Synthesis of compound 2. 1,2-Bis(4-bromophenyl)ethane-1,2-dione (500 mg, 1.36 mmol) and compound 1 (1250 mg, 3.27 mmol) were dissolved in K2CO3 (2 M, 6 mL) aqueous solution and THF (24 mL), and Pd(PPh3)4 (160 mg, 0.14 mmol) was added under nitrogen atmosphere. After stirring at 80 °C for 48 h, after cooling down to room temperature, the mixture was extracted with ethyl acetate and washed with water for three times. Finally, the product was dried under vacuum to give a white solid without further purification (2.2 g, yield: 96%). 1H NMR (600 MHz, Chloroform-d): δ 7.35–7.33 (m, 2H), 7.30–7.29 (m, 3H), 7.14–7.13 (t, J = 7.4 Hz, 2H), 7.05–7.02 (m, 4H), 7.04–7.03 (m, 2H), 6.96–6.95 (m, 2H), 1.12 (s, 12H). HR-MS ESI (m/z) [M + Na]+ [C26H27NO2Na]+ calc. 450.2001, found 450.2001.

Synthesis of compound 1. Bromotriphenylenylmethane (3.6 g, 14.32 mmol), Pd(PPh3)4 (420 mg, 0.60 mmol) and K2CO3 (2 M, 12 mL) aqueous solution were dissolved in 1,4-dioxane (48 mL) under nitrogen atmosphere. Then, the mixture was stirred at 90 °C for 48 h. After cooling down to room temperature, the mixture was extracted with ethyl acetate and washed with water for three times. Finally, the product was dried under vacuum to give a white solid without further purification (2.2 g, yield: 96%). 1H NMR (600 MHz, Chloroform-d): δ 7.35–7.33 (m, 2H), 7.30–7.29 (m, 3H), 7.14–7.13 (t, J = 7.4 Hz, 2H), 7.05–7.02 (m, 4H), 7.04–7.03 (m, 2H), 6.96–6.95 (m, 2H), 1.12 (s, 12H). HR-MS ESI (m/z) [M + Na]+ [C26H27BO2Na]+ calc. 407.2950, found 407.2954.

Concentration of BTPE-NO2@F127 in water or PBS = weight of nanoparticles + weight of solution × 100% volume of solution (1)

Loading capacity % = weight of BTPE – NO2@F127 in the nanoparticles weight of the nanoparticles × 100% (2)

Encapsulation efficiency % = weight of BTPE – NO2@F127 in the nanoparticles weight of the feeding BTPE – NO2@F127 × 100% (3)

The loading capacity was determined as 9.3% and the encapsulation efficiency was 98%.
Determination and calculation of fluorescence quantum yield. The NIR-II fluorescence quantum yield was determined as follows. The NIR-II fluorescent dye IR-26 was used as the reference. IR-26 solutions dissolved in 1,2-dichloroethane were prepared with different concentrations corresponding to different absorbance values at 808 nm, and then the absorption spectra and NIR-II fluorescent spectra (excited at 808 nm) of the solutions were recorded. The absorption spectra and NIR-II fluorescent spectra were measured for the BTPE-NH2@F127 solution (in PBS) and BTPE-NH2, solution (in PBS containing 5% DMSO). All NIR-II fluorescent spectra were integrated in the 900–1400 nm range. The integrated NIR-II fluorescence intensity (900–1400 nm) was plotted against the absorbance at 808 nm and fitted into linear function. Two slopes, one from the reference of IR-26 (quantum yield 0.1) in dichloroethane, and the other from BTPE-NH2@F127 (in PBS) or BTPE-NH2 (in PBS containing 5% DMSO), were adopted for the calculation of the quantum yield. The fluorescence quantum yield was calculated as follows:

\[ Q' \text{fluorescence} = \frac{Q_{\text{sample}}}{Q_{\text{ref}}} \text{fluorescence} \]

\[ \text{slope}_{\text{sample}} = \text{slope}_{\text{ref}} \times \frac{Q_{\text{sample}}}{Q_{\text{ref}}} \]

where \( Q' \text{fluorescence} \) represents the fluorescence quantum yield of IR-26 in dichloroethane, \( Q_{\text{fluorescence}} \text{sample} \) represents the fluorescence quantum yield of BTPE-NH2@F127 in PBS or BTPE-NH2 in PBS containing 5% DMSO, \( \text{ref} \) represents the refractive index of PBS solution or PBS containing 5% DMSO, and \( n_{\text{sample}} \) represents the refractive index of 1,2-dichloroethane.

Optical response of the nanoprobe BTPE-NO2@F127 in solution. The absorption, optoacoustic and fluorescence signal changes of the nanoprobe BTPE-NO2@F127 upon the addition of varied amounts of H2O2 (final BTPE-NO2@F127 nanoparticle concentration: 350 μg·mL⁻¹, namely BTPE-NO2 32.6 μg·mL⁻¹) in PBS (10 mM, pH 7.4) at 37 °C were recorded after 90 min upon mixing. For time-dependent experiments, the solutions were kept at 37 °C for different time periods before spectral measurements. For selectivity experiments, H2O2 and/or other substances were added into BTPE-NO2@F127 dispersions in PBS (10 mM, pH 7.4). Afterwards, optoacoustic and fluorescence signal intensities of the dispersions were recorded. The NIR-II fluorescence emission spectra were measured with the excitation of the 808 nm laser irradiation at 80 mW cm⁻².  

Cell culture, cytotoxicity studies and cell imaging. Murine macrophage cell line (RAW264.7) was obtained from KeyGen Biotech Co. Ltd (Nanjing, China). RAW264.7 cells were cultured in Dulbecco’s modified eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin and streptomycin at 37 °C in 5% CO2 atmosphere. The viabilities of RAW264.7 cells that were supplemented with 10% fetal bovine serum (FBS) and 1% penicillin and streptomycin at 37 °C in 5% CO2 atmosphere. The viabilities of RAW264.7 cells that were supplemented with 10% fetal bovine serum (FBS) and 1% penicillin and streptomycin were fully incubated with H2O2 for 1 h. Afterwards, the cells were seeded in 96-well plates at 5000 cells/well and cultured for 24 h. For imaging of IC syndrome, 1% isoflurane was delivered with nose cone for mouse anesthesia, and the mice were intravenously injected with the nanoprobe BTPE-NO2@F127 dispersion (PBS, BTPE-NO2 2.3 mg kg⁻¹) into the bladder via a 24-gauge catheter. After 15 min, the catheter was pulled out, the mice were anesthetized with continuous isoflurane and imaged. For imaging of trazodone-induced liver injury, mice were anesthetized by inhalation 1% isoflurane and the ischemia was performed using atrumatic vascular clamp. After 30 min or 60 min of ischemia, the clamp was removed, followed by suturing the abdominal cavity layer by layer and then reperfusion for 24 h.

Mouse model of interstitial cystitis. The interstitial cystitis mouse model was established according to the previous report. Briefly, female mice (7–8 weeks old) were randomly divided into five groups by body weight, including saline injection, the imaging was performed at varied time periods post i.v. injection of the nanoprobe.

Trazodone-induced liver injury mouse model. Male mice (7–8 weeks old) were randomly divided into groups with five mice per group, including sufficient replication of results with a reduction in animal number. For trazodone-induced liver injury, groups of male mice were treated with varied dosages of trazodone hydrochloride (50, 100 and 200 mg kg⁻¹) or isovolumic saline (control group) via intraperitoneal administration for three consecutive days. 6 h later after the last injection, the imaging was performed at varied time periods post i.v. injection of the nanoprobe.

Liver ischemia/reperfusion injury mouse model. The liver ischemia/reperfusion injury mouse model was established according to previous report. The male BALB/C mice (7–8 weeks old) were randomly divided into three groups, namely, the sham-surgery group (n = 5), the short ischemia group (n = 5) and the long ischemia group (n = 5). The mice in the sham-surgery group were given a midline laparotomy surgery without ischemia. The mice in the short ischemia group were given a midline laparotomy surgery, and ischemia was induced by clamping the hepatic artery and portal vein for 30 min followed by reperfusion for 24 h. The mice in the long ischemia group were given a midline laparotomy surgery, and ischemia was induced by clamping the hepatic artery and portal vein for 60 min followed by reperfusion for 24 h. During the midline laparotomy surgery, the mice were anesthetized by inhaling 1% isoflurane and the ischemia was performed using atrumatic vascular clamp. After 30 min or 60 min of ischemia, the clamp was removed, followed by suturing the abdominal cavity layer by layer and then reperfusion for 24 h.

In vivo NIR-II fluorescent imaging. The mice were placed in the supine posture. For imaging of IC syndrome, 1% isoflurane was delivered with nose cone for mouse anesthesia, and the mice were intravenously injected with the nanoprobe BTPE-NO2@F127 dispersion (in PBS, BTPE-NO2 2.3 mg kg⁻¹) into the bladder via a 24-gauge catheter. After 15 min, the catheter was pulled out, the mice were anesthetized with continuous isoflurane and imaged. For imaging of trazodone-induced liver injury and liver ischemia/reperfusion injury, the mice were treated by i.v. injection of the nanoprobe BTPE-NO2@F127 dispersion (equivalent to 9.1 mg kg⁻¹ of BTPE-NO2). The excitation light was provided by an 808 nm laser with a power density at the imaging plane of 50 mW cm².

Multispectral optoacoustic tomography imaging. All in vitro phantom and in vivo mouse optoacoustic imaging experiments were carried out on a multi-spectral optoacoustic tomographic imaging system.

For phantom experiments, the test solution or the control (PBS) was fully filled in commercial Wilmad NMR tubes respectively and then fixed on the holder of the imaging instrument. In vitro optoacoustic images of the nanoprobe BTPE-NO2@F127 in the presence of H2O2 of varied concentrations were acquired (signal at 680 nm).

For in vivo MSOT imaging experiments of the IC mouse model, the mice were anesthetized by 1% isoflurane delivered with nose cone. After intravenous injection with the nanoprobe BTPE-NO2@F127 dispersion (in PBS, BTPE-NO2 2.3 mg kg⁻¹) into the bladder via a 24-gauge catheter, the mice were imaged in the prone position in a water bath at 34 °C, and anesthesia and oxygen were supplied using a breathing mask. The following imaging wavelengths were selected by considering the major turning points in the absorption spectra of BTPE-NH2 and hemoglobin: 680 nm, 790 nm, 730 nm, 760 nm, 800 nm, 850 nm (background) and 900 nm. For each wavelength, 10 individual frames were recorded. The z-stack of the cross-sectional images created the orthogonal-view three-dimensional (3D) images. As for in vivo MSOT imaging experiments of the trazodone-induced liver injury mouse model and the liver ischemia/reperfusion injury mouse model, the nanoprobe BTPE-NO2@F127 dispersion (in PBS, equivalent to 9.1 mg kg⁻¹ of BTPE-NO2) was i.v. injected and imaging was performed. Similarly, the trunk of the mice covering whole liver region with a step size of 0.3 mm was selected for MSOT imaging. Subsequently, guided ICA spectral unmixing was used to separate
signals coming from BTPE-NH₂ (the activated probe) and those from endogenous photo-absorbing elements in the body (e.g., hemoglobin). As for in vivo mouse imaging experiments, five mice were tested for every group.

Tissue histological evaluation. For the study of the IC model, 24 h after cyclophosphamide injection, the mice from different groups were euthanized and the bladder was excised. The bladder tissues were embedded in paraffin and sectioned to 4 μm for hematoxylin and eosin (H&E) staining.

For the study of the trazodone-induced liver injury model, 6 h after the trazodone injection (for the last time) on the third day, the mice from different groups were euthanized and the liver was excised for H&E staining.

For the study of the liver ischemia/reperfusion injury model, after reperfusion for 24 h, the livers from different groups were excised for H&E staining.

For biosafety study, healthy mice were intravenously injected with the nanoprobe BTPE-NO₂@F127 dispersion (BTPE-NO₂, 9.1 mg kg⁻¹) or isovolumic saline. After 24 h, the mice were euthanized and the corresponding organs (heart, liver, spleen, lung and kidney) were excised, and the organ tissues were embedded in paraffin and sectioned to 4 μm for H&E staining.

Serum biochemistry assessment. The serum was obtained from different groups and the indexes including alanine aminotransferase (ALT) and aspartate transaminase (AST) levels were measured by using Elisa kits.

Body weight measurements. For evaluating in vivo toxicity of BTPE-NO₂@F127 nanoprobe, body weights of mice were measured. For the body weight measurements, mice (n = 5 per group, 7 weeks old) were i.v. injected with the nanoprobe dispersion (BTPE-NO₂, 9.1 mg kg⁻¹) or isovolumic saline. The body weights of these mice were recorded for 7 days.

Statistical analysis. All experiments were repeated at least three times. Quantitative data were expressed as mean ± standard error (SD). NMR spectra were analyzed using Mestre Nova LITE v14.0.0.0–23239 software (Mestre lab Research S.L.). Statistical calculations were performed using OriginPro 2018 (64 bit) SR1 b9.5.1.195. Data analysis of absorption spectra and fluorescence spectra was performed using OriginPro 2018 (64 bit) SR1 b9.5.1.195.

Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

All the other data supporting the findings of this study are available within the article and its supplementary information files and from the corresponding author upon reasonable request.

Received: 27 May 2021; Accepted: 10 November 2021; Published online: 25 November 2021

References

1. Antaris, A. L. et al. A small-molecule dye for NIR-II imaging. Nat. Mater. 15, 235–242 (2016).
2. Hao, X. et al. Programmable chemotherapy and immunotherapy against breast cancer guided by multiplexed fluorescence imaging in the second near-infrared window. Adv. Mater. 30, 1804437 (2018).
3. Li, C. et al. Preoperative detection and intraoperative visualization of brain tumors for more precise surgery: a new dual-modality MRI and NIR nanoprobe. Small 11, 4517–4525 (2015).
4. Wang, S. et al. Anti-quenching NIR-II molecular fluorophores for in vivo high-contrast imaging and pH sensing. Nat. Commun. 10, 1058 (2019).
5. Wu, W. et al. Molecular engineering of an organic NIR-II fluorophore with aggregation-induced emission characteristics for in vivo imaging. Small 15, 1905549 (2019).
6. Li, S. et al. In vivo real-time pharmaceutical evaluations of near-infrared II fluorescent nanomedicine bound polyethylene glycol ligands for tumor photothermal ablation. ACS Nano 14, 13681–13690 (2020).
7. Yang, Q. et al. Donor engineering for NIR-II molecular fluorophores with enhanced fluorescence performance. J. Am. Chem. Soc. 140, 1715–1724 (2018).
8. Zhu, Q. et al. Engineering oxaloplatin prodrug nanoparticles for second near-infrared fluorescence imaging-guided immunotherapy of colorectal cancer. Small 17, 2007882 (2021).
9. Antaris, A. L. et al. A high quantum yield molecule-protein complex fluorophore for near-infrared II imaging. Nat. Commun. 8, 15269 (2017).
10. Lin, J. et al. Novel near-infrared II aggregation-induced emission dots for in vivo bioimaging. Chem. Sci. 10, 1219–1226 (2019).
11. Qi, J. et al. Boosting fluorescence-photocoustic-acoustic-raman properties in one fluorophore for precise cancer surgery. Chem. 5, 2657–2677 (2019).
12. Sun, Y. et al. Novel benzo-bis(1,2,5-thiadiazole) fluorophores for in vivo NIR-II imaging of cancer. Chem. Sci. 7, 6203–6207 (2016).
13. Li, S. et al. Phenothiazine versus phenoxazine: structural effects on the photophysical properties of NIR-II AIE fluorophores. ACS Appl. Mater. Interfaces 12, 43466–43473 (2020).
14. Alifu, N. et al. Single-molecular near-infrared-II theranostic systems: ultrastable aggregation-induced emission nanoparticles for long-term tracing and efficient photothermal therapy. ACS Nano 12, 11282–11293 (2018).
15. Qu, J. et al. Real-time and high-resolution bioimaging with bright aggregation-induced emission dots in short-wave infrared region. Adv. Mater. 30, 1706856 (2018).
16. Shou, K. et al. Multifunctional biomedical imaging in physiological and pathological conditions using a NIR-II probe. Adv. Funct. Mater. 27, 1700995 (2017).
17. Li, Y. et al. Design of AIEgens for near-infrared III imaging through structural modulation at molecular and morphological levels. Nat. Commun. 11, 1255 (2020).
18. Gao, S. et al. Albumin tailoring fluorescence and photothermal conversion effect of near-infrared-II fluorophore with aggregation-induced emission characteristics. Nat. Commun. 10, 2206 (2019).
19. Li, S. et al. Self-assembled AIEgen nanoparticles for multiscale NIR-II vascular imaging. Biomaterials 264, 120365 (2021).
20. Sheng, Z. et al. Centimeter-deep NIR-II fluorescence imaging with nontoxic AIE probes in nonhuman primates. Research 2020, 4074593 (2020).
21. Liu, S. et al. Constitutional isomerization enables bright NIR-II AIEgen for brain-inflammation imaging. Adv. Funct. Mater. 30, 1908125 (2019).
22. Liu, S. et al. Molecular motion in aggregates: manipulating TICT for boosting photothermal theranostics. J. Am. Chem. Soc. 141, 5359–5368 (2019).
23. Mei, J. et al. Aggregation-induced emission: the whole is more brilliant than the parts. Adv. Mater. 26, 5429–5479 (2014).
24. Yang, J. et al. Aggregation-induced emission: a coming-of-age ceremony at the age of eighteen. Sci. China Chem. 62, 1090–1098 (2019).
25. Feng, G. et al. Ultrabright organic dots with aggregation-induced emission characteristics for cell tracking. Biomaterials 35, 8669–8677 (2014).
26. Guo, Z., Yan, C. & Zhu, W. H. High-performance quinoline-malonitrile core as a building block for the diversity-oriented synthesis of AIEgens. Angew. Chem. Int. Ed. 59, 9812–9825 (2020).
27. Ouyang, J. et al. Nanoprobe for breast cancer metastasis through multispectral optoacoustic tomography and aggregation-induced NIR-I/II fluorescence imaging. Angew. Chem. Int. Ed. 59, 10111–10121 (2020).
28. Ding, D. et al. Ultrabright organic dots with aggregation-induced emission characteristics for real-time two-photon intravital vascular imaging. Adv. Mater. 25, 6083–6088 (2013).
29. Li, Y. et al. Novel NIR-II organic fluorophores for bioimaging beyond 1550 nm. Chem. Sci. 11, 2621–2626 (2020).
30. Xu, P. et al. Molecular engineering of a high quantum yield NIR-II molecular fluorophore with aggregation-induced emission (AIE) characteristics for in vivo imaging. Nanoscale 12, 5084–5090 (2020).
31. Harmatsy, K. M. et al. Multipronged biomimetic approach to create optically tunable nanophotonic antennas. Angew. Chem. Int. Ed. 57, 8125–8129 (2018).
32. Tian, Y. et al. In-situ imaging of azoresudactase activity in the acute and chronic ulcerative colitis mice by a near-infrared fluorescent probe. Anal. Chem. 91, 10901–10907 (2019).
33. Hong, G., Antaris, A. L. & Dai, H. Near-infrared fluorophores for biomedical imaging. Nat. Biomed. Eng. 1, 0010 (2017).
34. Lya, Y. & Pu, K. Recent advances of activatable molecular probes based on semiconductor polymer nanoparticles in sensing and imaging. Adv. Sci. 4, 1600481 (2017).
35. Li, B. et al. Tumor inhibition achieved by targeting and regulating multiple key elements in EGFR signaling pathway using a self-assembled nanoprodug. Adv. Funct. Mater. 28, 1806902 (2018).
36. Wu, Y. et al. Activatable probes for diagnosing and positioning liver injury and metastatic tumors by multispectral optoacoustic tomography. Nat. Commun. 9, 3983 (2018).
37. Jiang, X. et al. Photoacoustic imaging of nanoparticle transport in the kidneys at high temporal resolution. Angew. Chem. Int. Ed. 58, 5994–6000 (2019).
38. Knox, H. J. et al. A bioreducible N-oxide-based probe for photoacoustic imaging of hypoxia. Nat. Commun. 8, 1794 (2017).
39. Liu, Y. et al. Ratiometric photoacoustic molecular imaging for methymercury detection in living subjects. Adv. Mater. 29, 1606129 (2017).
40. Wu, Y. et al. A nanoprobe for diagnosing and mapping lymphatic metastasis of tumor using 3D multispectral optoacoustic tomography owing to aggregation/deaggregation induced spectral change. Adv. Funct. Mater. 29, 1807960 (2019).
Lin, L. et al. High-speed three-dimensional photoacoustic computed tomography for preclinical research an clinical translation. Nat. Commun. 12, 882 (2021).

Chen, R. et al. Photoacoustic molecular imaging-escorted adipose photodynamic–browning synergy for fighting obesity with virus-like complexes. Nat. Nanotechnol. 16, 455–465 (2021).

Xiang, H. et al. Self-assembled organic nanomedicine enables ultrastable photo-to-heat converting theranostics in the second near-infrared biowindow. Nat. Commun. 13 (2021).

Wu, Y., Zeng, F., Zhao, Y. L. & Wu, S. Emerging contrast agents for multispectral optoacoustic imaging and their biomedical applications. Chem. Soc. Rev. 50, 7924–7940 (2021).

Hanno, P. M., Erickson, D., Moldwin, R. & Faraday, M. M. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline endorsement. J. Urol. 197, 1545–1553 (2015).

Chen, Y. T. et al. Melatonin treatment further improves adipose-derived mesenchymal stem cell therapy for acute interstitial cystitis in rat. J. Pineal Res. 57, 248–261 (2014).

Patrick, B. A., Das, A. & Jaiswal, A. K. NAD(P)H: quinone oxidoreductase 1 protects bladder epithelium against painful bladder syndrome in mice. Free Radic. Biol. Med. 53, 1886–1893 (2012).

Barnes, H. et al. Cyclophosphamide for connective tissue disease-associated interstitial lung disease. Cochrane Database Syst. Rev. 1, CD010908 (2018).

Birder, L. A. & Groat, W. C. D. Mechanisms of disease: involvement of the urothelium in bladder dysfunction. Nat. Rev. Urol. 4, 46–54 (2007).

Liu, X. Y., Zhu, M. X. & Xie, J. P. Mutagenicity of acrolein and acrolein-induced DNA adducts. Toxicol. Mech. Methods 20, 36–44 (2010).

Ntziafristos, V. & Razansky, D. Molecular imaging by means of multispectral optoacoustic tomography (MSOT). Chem. Rev. 110, 2783–2794 (2010).

Hudson, S. V. et al. Targeted Non-invasive imaging of EGF-expressing orthotopic pancreatic cancer using multispectral optoacoustic tomography (MSOT). Biomed. Opt. Express 5, 6271–6279 (2014).

Jo, J., Lee, C. H., Kopelman, R. & Wang, X. In vivo quantitative imaging of tumor pH by nanosorbent assisted multispectral optoacoustic imaging. Nat. Commun. 8, 471 (2017).

Gujrati, V., Mishra, A. & Ntziafristos, V. Molecular imaging probes for multispectral optoacoustic tomography. Chem. Commun. 53, 4653–4672 (2017).

Tomaszewski, M. R. et al. Oxygen enhanced optoacoustic tomography (OE-OT) Reveals vascular dynamics in murine models of prostate cancer. Theranostics 7, 2900–2913 (2017).

Voican, C. S., Corruble, E., Naveau, S. & Perlemuter, G. Antidepressant-induced liver injury: a review for clinicians. Am. J. Psychiat. 171, 404–415 (2014).

Carvalhana, S. et al. Acute liver failure due to trazodone and diazepam. GE Port. J. Gastroenterol. 24, 40–42 (2017).

Coro, P. et al. Forty percent and eighty percent methionine restriction decrease mitochondrial ROS generation and oxidative stress in rat liver. Biogerontology 9, 183–196 (2008).

Abu-Amara, M. et al. Liver ischemia/reperfusion injury: processes in inflammatory networks - a review. Liver Transpl. 16, 1016–1032 (2010).

de Rougemont, O., Lehmann, K. & Clavien, P. A. Preconditioning, organ preservation, and postconditioning to prevent ischemia- reperfusion injury to the liver. Liver Transpl. 15, 1172–1182 (2009).

Moon, K. H. et al. Oxidative inactivation of key mitochondrial proteins leads to dysfunction and injury in hepatic ischemia reperfusion. Gastroenterology 135, 1344–1357 (2008).

Liu, Y. et al. Protective effects of hydrogen enriched saline on liver ischemia reperfusion injury by reducing oxidative stress and HMGB1 release. BMC Gastroenterol. 14, 12 (2014).

Liu, Y. X. et al. Sirolimus attenuates reduced-size liver ischemia–reperfusion injury but impairs liver regeneration in rats. Dig. Dis. Sci. 55, 2255–2262 (2010).

Malley, S. E. & Vizzard, M. A. Changes in urinary bladder cytokine mRNA and protein after cyclophosphamide-induced cystitis. Physiol. Genomics 9, 5–13 (2002).

Bellantis, F. et al. Propofol but not sevoflurane prevents mitochondrial dysfunction and oxidative stress by limiting HIF-1a activation in hepatic ischemia/reperfusion injury. Free Radic. Biol. Med. 96, 323–333 (2016).

Acknowledgements
This work was supported by the National Natural Science Foundation of China (No. 21788102 to S.W. and No. 21875069 to F.Z.), the National Science Foundation of Guangdong Province (No. 2016A030312002 to S.W.), and the Fund of Guangdong Provincial Key Laboratory of Luminescence from Molecular Aggregates (No. 2019B030301003 to S.W.). The work was also supported by the Singapore Agency for Science, Technology and Research (A*STAR) AME IRG grant (No. A20E5c0081 to Y.Z.) and the Singapore National Research Foundation Investigatorship (No. NRF-NRFI2018-03 to Y.Z.).

Author contributions
Y.Z., S.W., F.Z., and J.C. conceived the project. J.C. and L.C. designed the chemical adaptation, distribution and reproduction in any medium or format, as long as you give the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41467-021-27233-4.

Correspondence and requests for materials should be addressed to Fang Zeng, Shuizhu Wu or Yanli Zhao.

Peer review information Nature Communications thanks Homan Kang and the other anonymous reviewers for their contribution to the peer review of this work. Peer reviewer reports are available.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.